Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: Implications for the treatment of methamphetamine dependence

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Simmler, Linda D ^a   Wandeler, Rebecca ^a   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Addiction; Bupropion; Dopamine; Dopamine transporter; MDPV; Methamphetamine; Methylphenidate

Indexed keywords

MUSCOVY DUCK PARVOVIRUS;

1,3 BENZODIOXOLE DERIVATIVE; 3,4 METHYLENEDIOXYPYROVALERONE; 3,4-METHYLENEDIOXYPYROVALERONE; AMFEBUTAMONE; DOPAMINE; METHAMPHETAMINE; METHYLPHENIDATE; PYRROLIDINE DERIVATIVE;

ARTICLE; DRUG ABUSE; DRUG ANTAGONISM; HUMAN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

AMPHETAMINE-RELATED DISORDERS; BENZODIOXOLES; BIOLOGICAL TRANSPORT; BUPROPION; DOPAMINE; HUMANS; METHAMPHETAMINE; METHYLPHENIDATE; PYRROLIDINES;

EID: 84878469808     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-220     Document Type: Article

References (40)

1. Pharmacological approaches to methamphetamine dependence: a focused review. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL, Br J Clin Pharmacol 2010 69 6 578 592 10.1111/j.1365-2125.2010.03639.x 20565449
2. Release of dopamine via the human transporter. Eshleman AJ, Henningsen RA, Neve KA, Janowsky A, Mol Pharmacol 1994 45 2 312 316 7906856
3. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS, Synapse 2001 39 1 32 41 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 11071707
4. Dopamine and reward: the anhedonia hypothesis 30 years on. Wise RA, Neurotox Res 2008 14 2-3 169 183 19073424
5. How addictive drugs disrupt presynaptic dopamine neurotransmission. Sulzer D, Neuron 2011 69 4 628 649 10.1016/j.neuron.2011.02.010 21338876
6. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. Han DD, Gu HH, BMC Pharmacol 2006 6 6 16515684
7. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S, Primary care companion to the Journal of clinical psychiatry 2004 6 4 159 166 10.4088/PCC.v06n0403 15361919
8. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Tatsumi M, Groshan K, Blakely RD, Richelson E, Eur J Pharmacol 1997 340 2-3 249 258 9537821
9. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT, CNS Drug Rev 2006 12 3-4 178 207 17227286
10. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. Meltzer PC, Butler D, Deschamps JR, Madras BK, J Med Chem 2006 49 4 1420 1432 10.1021/jm050797a 16480278
11. Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine. Carroll FI, Muresan AZ, Blough BE, Navarro HA, Mascarella SW, Eaton JB, Huang X, Damaj MI, Lukas RJ, J Med Chem 2011 54 5 1441 1448 10.1021/jm1014555 21319801
12. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Schachter HM, Pham B, King J, Langford S, Moher D, CMAJ 2001 165 11 1475 1488 11762571
13. Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. Vitiello B, CMAJ 2001 165 11 1505 1506 11762576
14. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Newton TF, Roache JD, De La Garza R 2nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R, Neuropsychopharmacology 2006 31 7 1537 1544 10.1038/sj.npp.1300979 16319910
15. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, De La Garza R, Newton T, Ling W, Drug Alcohol Depend 2008 96 3 222 232 10.1016/j.drugalcdep.2008.03.010 18468815
16. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Brensilver M, Heinzerling KG, Swanson AN, Shoptaw SJ, Drug Alcohol Depend 2012 125 1-2 169 72 10.1016/j.drugalcdep.2012.03.027 22534658
17. Bupropion for the treatment of methamphetamine dependence. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Neuropsychopharmacology 2008 33 5 1162 1170 10.1038/sj.npp.1301481 17581531
18. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. McCann DJ, Li SH, CNS Neurosci Ther 2012 18 5 414 418 10.1111/j.1755-5949.2011. 00263.x 22070720
19. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Tiihonen J, Kuoppasalmi K, Fohr J, Tuomola P, Kuikanmaki O, Vorma H, Sokero P, Haukka J, Meririnne E, Am J Psychiatry 2007 164 1 160 162 10.1176/appi.ajp.164.1.160 17202560
20. Bupropion attenuates methamphetamine self-administration in adult male rats. Reichel CM, Murray JE, Grant KM, Bevins RA, Drug Alcohol Depend 2009 100 1-2 54 62 19010609
21. Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Schindler CW, Gilman JP, Panlilio LV, McCann DJ, Goldberg SR, Exp Clin Psychopharmacol 2011 19 1 1 10 21341918
22. Neurocircuitry of addiction. Koob GF, Volkow ND, Neuropsychopharmacology 2010 35 1 217 238 10.1038/npp.2009.110 19710631
23. The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M, Sleep 2009 32 11 1425 1438 19928382
24. Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ, Yao WD, Madras BK, Miller GM, J Pharmacol Exp Ther 2007 321 1 116 127 10.1124/jpet.106.116863 17234900
25. Pharmacological characterization of designer cathinones in vitro. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME, Br J Pharmacol 2013 168 458 470 10.1111/j.1476-5381.2012.02145.x 22897747
26. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Hoener MC, Liechti ME, PLoS One 2012 7 36476 10.1371/journal.pone.0036476 22574166
27. Clinical profile of the novel antidepressant bupropion. Stern WC, Harto-Truax N, Rogers J, Miller L, Adv Biochem Psychopharmacol 1982 32 21 34 6807060
28. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Rothman RB, Life Sci 1990 46 20 L17 21 10.1016/0024-3205(90)90466-5 2111866
29. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Martin WR, Sloan JW, Sapira JD, Jasinski DR, Clin Pharmacol Ther 1971 12 2 245 258 5554941
30. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Liebermann J, Hitzemann R, Arch Gen Psychiatry 1995 52 6 456 463 10.1001/archpsyc.1995.03950180042006 7771915
31. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK, Psychopharmacology 2009 204 1 73 83 10.1007/s00213-008-1439-6 19104775
32. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Kollins SH, MacDonald EK, Rush CR, Pharmacol Biochem Behav 2001 68 3 611 627 10.1016/S0091-3057(01)00464-6 11325419
33. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Spiller HA, Ryan ML, Weston RG, Jansen J, Clin Toxicol (Phila) 2011 49 6 499 505 10.3109/15563650.2011.590812
34. 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Coppola M, Mondola R, Toxicol Lett 2012 208 1 12 15 10.1016/j.toxlet.2011.10.002 22008731
35. Potent reinforcing effects of the synthetic cathinone methylenedioxypyrovalerone (MDPV) in rats. Watteron LR, Kufahl PR, Nemirovsky NE, Sewalia K, Olive MF, Neuropsychopharmacology 2011 36 440
36. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C, J Neurochem 1998 71 3 1289 1297 9721755
37. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME, Clin Pharmacol Ther 2011 90 2 246 255 10.1038/clpt.2011.78 21677639
38. A perhaps unexpected role of norepinephrine in actions of MDMA. Newton TF, Clin Pharmacol Ther 2011 90 2 215 216 10.1038/clpt.2011.125 21772299
39. Norepinephrine and stimulant addiction. Sofuoglu M, Sewell RA, Addict Biol 2009 14 2 119 129 10.1111/j.1369-1600.2008.00138.x 18811678
40. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS, Biol Psychiatry 2010 68 9 854 860 10.1016/j.biopsych.2010.06.017 20691429